Although several definitions of kidney-specific and cardiorenal composite end points have been evaluated in SGLT2 inhibitor trials, this exploratory analysis focused on a composite outcome using a first event of 50% decline in eGFR, kidney failure, CV death, or kidney death and demonstrated that sotagliflozin reduced the risk of this end point by 23% compared with placebo in patients with type 2 diabetes and CKD, suggesting a kidney protective effect with sotagliflozin in patients with type 2 diabetes and CKD. The gene discussed is SLC5A2; the disease is kidney failure.